MX9805724A - Aplicaciones terapeuticas de la tecnologia t-bam (cd40-l) para tratar enfermedades inflamatorias del riñon que tienen puntos de iniciacion diferentes de la deposicion de autoanticuerpos. - Google Patents

Aplicaciones terapeuticas de la tecnologia t-bam (cd40-l) para tratar enfermedades inflamatorias del riñon que tienen puntos de iniciacion diferentes de la deposicion de autoanticuerpos.

Info

Publication number
MX9805724A
MX9805724A MX9805724A MX9805724A MX9805724A MX 9805724 A MX9805724 A MX 9805724A MX 9805724 A MX9805724 A MX 9805724A MX 9805724 A MX9805724 A MX 9805724A MX 9805724 A MX9805724 A MX 9805724A
Authority
MX
Mexico
Prior art keywords
cd40l
bam
technology
kidney diseases
therapeutic applications
Prior art date
Application number
MX9805724A
Other languages
English (en)
Inventor
Michael J Yellin
Seth Lederman
Leonard Chess
Mihail KARPUSAS
David W Thomas
Original Assignee
Univ Columbia
City Of New York
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia, City Of New York, Biogen Inc filed Critical Univ Columbia
Publication of MX9805724A publication Critical patent/MX9805724A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • External Artificial Organs (AREA)

Abstract

Se inhibe la activacion por el ligando de CD40 de células renales que llevan CD40 sobre la superficie celular, ambos in vivo y ex vivo, con un agente capaz de inhibir la interaccion entre el ligando de CD40 y CD40 sobre las células. Se tratan enfermedades inflamatorias del riñon que tienen puntos de iniciacion diferentes de la deposicion del autoanticuerpo.
MX9805724A 1996-01-16 1998-07-16 Aplicaciones terapeuticas de la tecnologia t-bam (cd40-l) para tratar enfermedades inflamatorias del riñon que tienen puntos de iniciacion diferentes de la deposicion de autoanticuerpos. MX9805724A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58733496A 1996-01-16 1996-01-16
US64147396A 1996-05-01 1996-05-01

Publications (1)

Publication Number Publication Date
MX9805724A true MX9805724A (es) 1998-10-31

Family

ID=27079989

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9805724A MX9805724A (es) 1996-01-16 1998-07-16 Aplicaciones terapeuticas de la tecnologia t-bam (cd40-l) para tratar enfermedades inflamatorias del riñon que tienen puntos de iniciacion diferentes de la deposicion de autoanticuerpos.

Country Status (6)

Country Link
EP (1) EP0874637A1 (es)
JP (1) JP2000503659A (es)
AU (1) AU1748897A (es)
CA (1) CA2243531A1 (es)
MX (1) MX9805724A (es)
WO (1) WO1997026000A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200001248T2 (tr) * 1997-01-10 2000-07-21 Biogen,Inc. Anti-CD40L bileşikleri ile lupus nefritis tedavisi
AU776341B2 (en) * 1999-08-19 2004-09-02 Kurokawa, Kiyoshi Meg-1 protein
AU2001261585B2 (en) 2000-05-12 2006-08-31 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
CN110546164B (zh) * 2016-11-11 2023-10-20 锦湖Ht株式会社 特异性结合cd40的抗体及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same

Also Published As

Publication number Publication date
AU1748897A (en) 1997-08-11
EP0874637A1 (en) 1998-11-04
CA2243531A1 (en) 1997-07-24
JP2000503659A (ja) 2000-03-28
WO1997026000A1 (en) 1997-07-24

Similar Documents

Publication Publication Date Title
GB9807639D0 (en) Anti-inflammatory agents
GEP20033092B (en) Purine Inhibitors of Cyclin Dependent Kinase 2 and Ik-Aa
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
NZ505011A (en) Expression vectors and cell lines expressing VEGF-D and method of treating melanomas
WO2005052139A3 (en) Method of inducing memory b cell development and terminal differentiation
MY136037A (en) Biphenyl pyrimidone lp-pla2 inhibitors
CA2238879A1 (en) Thereapeutic applications for the anti-t-bam (cd40-l) monoclonal antibody 5c8
EP0919622A3 (en) Surface expression of enzyme in gene directed prodrug therapy
AR007218A1 (es) Aparato y metodo para la generacion y utilizacion de iones ferricos.
EP1231914A4 (en) NORDIHYDROGUAIARTIC DERIVATIVES FOR USE IN THE TREATMENT OF TUMORS
AR022583A1 (es) Secuencias antitumorales anti-sentido dirigidas contra los componentes r1 y r2 de la reductasa de los ribonucleotidos
WO2001006990A3 (en) Use of etodolac to treat cancer
CA2330309A1 (en) Electric therapeutic device
AU5218998A (en) Reactive oxygen intermediates containing compounds effective in inducing cell differentiation of malignant cells such as leukemia
MX9805724A (es) Aplicaciones terapeuticas de la tecnologia t-bam (cd40-l) para tratar enfermedades inflamatorias del riñon que tienen puntos de iniciacion diferentes de la deposicion de autoanticuerpos.
IL135825A0 (en) Use of mirtazapine for treating sleep apneas
HK1029944A1 (en) Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway
CA2259962A1 (en) Therapeutic applications of t-bam (cd40l) technology to treat diseases involving smooth muscle cells
MX9606559A (es) Terapia para el cancer usando linfotoxina.
AU5168099A (en) Use of novel agents inducing cell death in synergy with interferons
ZA97657B (en) Ligand directed enzyme prodrug therapy.
EP0971725A4 (en) METHOD FOR TREATING SCAR TISSUE
AU2275697A (en) Use of cell membrane permeants in the treatment of cellular proliferative disea ses
CZ20011642A3 (cs) Léčivo pro prevenci progrese aterosklerózy u savců
HK1030887A1 (en) Treatment of bladder cancer by mycobacterium phleicell wall.